Yuh-Min Chen

Medical School

1978–1985 National Yang-Ming Medical College
1983–1985 Intern, Taipei Veterans General Hospital

Postgraduate Training

1987–1989 Resident, Medical Department, Uan-Chyan Veterans Hospital, Taiwan
1989–1992 Resident, Chest Department, Taipei Veterans General Hospital
1992–1993 Chief Resident, Chest Department, Taipei Veterans General Hospital
1993–1994 Fellow, Chest Department, Taipei Veterans General Hospital
1993–1995 Fellow, Cancer Clinical Research Center, Institute of Biomedical Sciences, Academia Sinica
1996–1997 Visiting Fellow, National Cancer Institute, National Institutes of Health, USA
1994–1998 Ph.D., Institute of Clinical Medicine, National Yang-Ming University

Academic Appointment

1991–present Board certified, Internal Medicine
1992–1997 Clinical Lecturer, Medical Department, National Yang-Ming University
1993–present Board certified, Chest Medicine
1994–2026 Attending Physician, Department of Chest Medicine, Taipei Veterans General Hospital
1995–present Board certified, Medical Oncology
1997–1999 Clinical Assistant Professor, School of Medicine, National Yang-Ming University
2004–2012 Clinical Associate Professor, School of Medicine, National Defense University
1998–2008 Adjunct Attending Physician, Institute of Cancer Research, National Health Research Institutes
1999–2002 Assistant Professor, School of Medicine, National Yang-Ming University
2002–2013 Associate Professor, School of Medicine, National Yang-Ming University
2008/8–2013 Clinical Professor, Taipei Medical University
2013–2022 Professor, College of Medical Science and Technology, Taipei Medical University
2015/9/1–2020/1/15 Chief, Division of General Chest Medicine, Department of Chest Medicine, Taipei Veterans General Hospital, Taipei
2016–2026 Chairman, Thoracic Oncology Multidisciplinary Team, Taipei Veterans General Hospital, Taipei
2016/2/1–present Professor, School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei
2020/01/16–2026/01/15 Head, Department of Chest Medicine, Taipei Veterans General Hospital, Taipei
2026/3/2– Head, Clinical Research Center, Shin Kong Wu Ho-Su Memorial Hospital, Taipei

Professional Interests and Specialties

Internal Medicine
Pulmonary and Critical Care Medicine
Medical Oncology, especially Thoracic Oncology
Cell Biology and Molecular Biology
Tumor Immunology
Chemotherapy
Targeted Therapy
Immunotherapy

Professional Societies

Member, European Society of Clinical Oncology
Member, American Society of Clinical Oncology
Member, International Association for the Study of Lung Cancer
Member, Asia-Pacific Society of Respirology Research Committee, 2020–present
Fellow, American College of Chest Physicians
Member, Society of Internal Medicine (Taiwan)
Member, Society of Ultrasound in Medicine (ROC)
Member, Taiwan Clinical Oncology Society
Member, Taiwan Cancer Society
Member, Taiwan Society of Respiratory and Intensive Care Medicine
Member, Chinese Medical Association (Taipei)
Member, Taiwan Lung Cancer Society
Member, Asia-Pacific Society of Respirology
Member, European Respiratory Society
Secretary, Taiwan Clinical Oncology Society, 1994–2001
Secretary General, Taiwan Lung Cancer Society, 2000–2008, 2009–2012
Secretary General, Taiwan Clinical Oncology Society, 2001–2007
Secretary General, 15th Taiwan Jointed Cancer Conference, May 2018, Taipei, Taiwan
President, Taiwan Clinical Oncology Society, 2007–2013
Audit, Taiwan Society of Palliative Medicine, 2008–2010
Director, Chinese Oncology Society, 2011–2013
Director, Taiwan Clinical Oncology Society, 2013–present
Member of Scientific Committee, 12th, 13th, and 14th World Conference on Lung Cancer, IASLC, 2007, 2009, 2011
Section Chair, 13th and 14th World Conference on Lung Cancer, IASLC, 2009 and 2011
Co-Chair, Organizing Committee, Taiwan Joint Cancer Conference, 2000–2013, 2016, 2017, 2019, 2020
Chair, Organizing Committee, Annual Meeting of Cross-Strait Academic Conference on Oncology, 2007–2014
Vice-Chair, Organizing Committee, bi-annual meeting of Chinese Anti-Cancer Society, 2007–2013
Organizing Committee, Round Asia Oncology Forum (RAOF) 2012, Taipei, Taiwan, 2012/8/31–2012/9/2
Committee member, Avastin global advisory board meeting, 15th World Conference on Lung Cancer (WCLC 2013), Sydney, Australia, October 31, 2013
Chair, Iressa Asia area advisory board meeting, Taipei, Taiwan, March 8, 2014
President, Taiwan Lung Cancer Society, 2015/05/08 – 2021/08/26
Chair, TLCS and IASLC Lung Cancer Symposium, October 28–29, 2017, Taipei, Taiwan
Chair, 23rd Taiwan Jointed Cancer Conference, May 5–6, 2018, Taipei, Taiwan
Committee member, 2nd Expanded Asia NSCLC Adboard Meeting for Afatinib, Taipei, Taiwan, October 6, 2018
Chair, 2020 Taiwan Lung Cancer Society International Symposium on Treatment Advances in Lung Cancer, Taipei, January 1–12, 2020
Councillor, Asia-Pacific Society of Respirology, 2024/Aug – present
President, The 9th Asia-Pacific Region Conference of the International Union Against Tuberculosis and Lung Disease and the 2024 Summer Meeting of the Taiwan Society of Pulmonary and Critical Care Medicine, 2024/4/26–2024/4/29, Taipei, Taiwan
President, The 10th Asian Pacific Congress on Bronchology and Interventional Pulmonology and the 2025 Summer Meeting of the Taiwan Society of Pulmonary and Critical Care Medicine, 2025/6/20–2025/6/22, Taipei, Taiwan
President, Taiwan Society of Pulmonary and Critical Care Medicine, 2023/12/14 – present
Secretary General, Asian Pacific Society of Respirology, 2025 Dec –

Job Title

Head

Faculty / Department / Division

Department of Clinical Research Center

Institution / Organisation

Shin Kong Wu Ho-Su Memorial Hospital

20 November 2026, Friday

Time	Session

11:00 12:00	S7: Lung Cancer - A Changing Paradigm David Lam Chi-Leung Chairperson Hong Kong Ernest Mau Ern Poh Chairperson Malaysia AI Radiomics for the Early Detection of Lung Cancer Ren Yuan Speaker Canada Overview of Lung Cancer in the Asia Pacific. Is It Different from Its Counterpart from Outside Asia? Chong Kin Liam Speaker Malaysia New Challenges of Lung Cancer Management in the Asian Pacific Region Yuh-Min Chen Speaker Taiwan "Background Lung cancer is the leading cause of cancer-related mortality in the Asia Pacific (APAC) region, accounting for approximately 60% of global cases. The demographic of lung cancer in this region is shifting, with increasing incidence among younger individuals, non-smokers, and women. Driven by diverse risk factors including air pollution, occupational hazards, genetic predisposition, and household cooking fumes, there is a pressing need for personalized approaches to screening, diagnosis, and treatment. Early Detection & Screening Low-dose computed tomography (LDCT) screening has been instrumental in shifting detection toward early-stage disease. While global trials primarily focus on heavy smokers, regional data indicates that genetic factors play a critical role. A nationwide screening program in Taiwan demonstrated that individuals with a family history of lung cancer have a higher detection rate of early-stage disease (89.6%) compared to heavy smokers (66.1%). This targeted screening approach has led to a significant stage shift and a projected 53% reduction in lung cancer mortality. Targeted Therapy & Immunotherapy Recent phase III trials evaluating targeted therapies (such as osimertinib, amivantamab plus lazertinib, and lorlatinib) and immunotherapies (including pembrolizumab and neoadjuvant nivolumab) show that clinical efficacy and toxicity profiles in Asian cohorts are highly consistent with global populations. Subgroup analyses from landmark trials, including FLAURA2, MARIPOSA, KEYNOTE-189, and CheckMate 816, confirm that APAC patients derive comparable progression-free survival (PFS), overall survival (OS), and pathological complete response (pCR) benefits from these advanced treatment modalities. Conclusions & Future Challenges Despite the biological efficacy of advanced treatments mirroring global outcomes, the APAC region faces unique, systemic challenges. Wide regional variations in healthcare infrastructure, drug pricing, and reimbursement criteria—along with underrepresentation in global clinical trials—create significant disparities in early diagnosis and treatment access. Overcoming these socio-economic barriers and optimizing management strategies in resource-limited settings remain the primary challenges for improving lung cancer survival rates across the Asia Pacific region. " Q&A Ballroom 3, Lower Ground Floor

Time

Session

11:00

12:00

S7: Lung Cancer - A Changing Paradigm

David Lam Chi-Leung Chairperson Hong Kong

Ernest Mau Ern Poh Chairperson Malaysia

AI Radiomics for the Early Detection of Lung Cancer

Ren Yuan Speaker Canada
Overview of Lung Cancer in the Asia Pacific. Is It Different from Its Counterpart from Outside Asia?

Chong Kin Liam Speaker Malaysia
New Challenges of Lung Cancer Management in the Asian Pacific Region

Yuh-Min Chen Speaker Taiwan

"Background Lung cancer is the leading cause of cancer-related mortality in the Asia Pacific (APAC) region, accounting for approximately 60% of global cases. The demographic of lung cancer in this region is shifting, with increasing incidence among younger individuals, non-smokers, and women. Driven by diverse risk factors including air pollution, occupational hazards, genetic predisposition, and household cooking fumes, there is a pressing need for personalized approaches to screening, diagnosis, and treatment. Early Detection & Screening Low-dose computed tomography (LDCT) screening has been instrumental in shifting detection toward early-stage disease. While global trials primarily focus on heavy smokers, regional data indicates that genetic factors play a critical role. A nationwide screening program in Taiwan demonstrated that individuals with a family history of lung cancer have a higher detection rate of early-stage disease (89.6%) compared to heavy smokers (66.1%). This targeted screening approach has led to a significant stage shift and a projected 53% reduction in lung cancer mortality. Targeted Therapy & Immunotherapy Recent phase III trials evaluating targeted therapies (such as osimertinib, amivantamab plus lazertinib, and lorlatinib) and immunotherapies (including pembrolizumab and neoadjuvant nivolumab) show that clinical efficacy and toxicity profiles in Asian cohorts are highly consistent with global populations. Subgroup analyses from landmark trials, including FLAURA2, MARIPOSA, KEYNOTE-189, and CheckMate 816, confirm that APAC patients derive comparable progression-free survival (PFS), overall survival (OS), and pathological complete response (pCR) benefits from these advanced treatment modalities. Conclusions & Future Challenges Despite the biological efficacy of advanced treatments mirroring global outcomes, the APAC region faces unique, systemic challenges. Wide regional variations in healthcare infrastructure, drug pricing, and reimbursement criteria—along with underrepresentation in global clinical trials—create significant disparities in early diagnosis and treatment access. Overcoming these socio-economic barriers and optimizing management strategies in resource-limited settings remain the primary challenges for improving lung cancer survival rates across the Asia Pacific region. "
Q&A

Ballroom 3, Lower Ground Floor